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 The corneal dystrophies are a heterogeneous group of
disorders that may lead to severe visual impairment [1]. Macu-
lar corneal dystrophy (MCD, MCDC1 [OMIM 217800]) is an
autosomal recessive disorder clinically characterized by bi-
lateral corneal opacification. Initially the patients have dif-
fuse, fine superficial clouding in the central stroma. The opaci-
ties extend through the entire thickness of the cornea and in-
volve the central and peripheral corneal stroma. The corneal
stroma is often thinner than normal [2-4]. The corneal endot-
helium is involved and guttae form on the Descemet’s mem-
brane [5]. The prevalence of MCD varies immensely in dif-
ferent parts of the world but in most populations the condition
is rare. In some countries MCD accounts for 10-75% of the
corneal dystrophies requiring corneal grafting [6,7].
Keratan sulfate (KS) is the major corneal glycosaminogly-
can [8] and is a component of three corneal proteoglycans
(lumican, keratocan, and mimecan). Sulfate ions contribute
significantly to the negative charge of proteoglycans and in
the cornea this highly anionic charge on KS is believed to
contribute to its ability to imbibe water and influence corneal
hydration, which must be critically controlled for the mainte-
nance of corneal transparency [9]. During corneal develop-
ment, sulfation of polylactosamine (non-sulfated precursor of
KS) occurs at later stages and is required for attainment of full
corneal transparency [10]. Macular corneal dystrophy arises
due to a failure to synthesize normal keratan sulfate
proteoglycan within the cornea [11-13] and corneas with this
disorder accumulate a glycoaminoglycan within the
keratocytes, corneal endothelium, Bowman’s layer, Descemet’s
membrane, and extracellularly in the stroma.
MCD is divided into three immunophenotypes (MCD
types I, IA, and II) based on the reactivity of the patient’s se-
rum and corneal tissue to an antibody that recognizes sulfated
KS, although these subtypes are clinically indistinguishable
from each other [14-16]. In MCD type I neither the serum nor
the corneal tissue contain antigenic KS (AgKS). In MCD type
IA, sulfated KS is absent in the cornea and the serum but can
be detected in the keratocytes [16]. MCD type II is character-
ized by the presence of AgKS in the corneal tissue and normal
levels of AgKS in the serum. After identifying the locus for
MCD on chromosome 16 [17] and fine mapping the gene
[18,19], mutations in the carbohydrate sulfotransferase gene
(CHST6) encoding corneal N-acetyl glucosamine-6-O-
sulfotransferase (C-GlcNAc-6-ST) were identified as the cause
of MCD types I and II [20]. While mutations of the coding
region of CHST6 were found in MCD types I, IA, and II, de-
letions and rearrangements of the upstream region of CHST6
as well as missense mutations have been reported in MCD
type II [20-22].
MCD is one of the most common types of corneal dystro-
phy in India and constitutes about 30% of all dystrophies re-
quiring penetrating keratoplasty (G.K. Vemuganti, personal
communication). We screened 36 patients with MCD belong-
ing to 31 families for mutations in the CHST6 gene. Our study
revealed 22 mutations 17 of which are novel, consisting of
deletions, insertions, missense, and nonsense mutations.
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Purpose: Macular corneal dystrophy (MCD) is an autosomal recessive disorder characterized by progressive central
haze, confluent punctate opacities and abnormal deposits in the cornea. It is caused by mutations in the carbohydrate
sulfotransferase-6 (CHST6) gene, encoding corneal N-acetyl glucosamine-6-O-sulfotransferase (C-GlcNAc-6-ST). We
screened the CHST6 gene for mutations in Indian families with MCD, in order to determine the range of pathogenic
mutations.
Methods: Genomic DNA was isolated from peripheral blood leukocytes of patients with MCD and normal controls. The
coding regions of the CHST6 gene were amplified using three pairs of primers and amplified products were directly
sequenced.
Results: We identified 22 (5 nonsense, 5 frameshift, 2 insertion, and 10 missense) mutations in 36 patients from 31
families with MCD, supporting the conclusion that loss of function of this gene is responsible for this corneal disease.
Seventeen of these mutations are novel.
Conclusions: These data highlight the allelic heterogeneity of macular corneal dystrophy in Indian patients.
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METHODS
Clinical evaluation and patient selection:  The study had the
approval of Institutional Review Boards of the L. V. Prasad
Eye Institute and Duke University Medical Center and con-
formed to the tenets of the declaration of Helsinki. Informed
consent was obtained from all participants for clinical and
molecular genetic studies. Patients were evaluated clinically
by a corneal specialist (M.S.S.). Patients were diagnosed as
having MCD based on typical clinical features. All patients
had a characteristic haze and whitish nodular lesions involv-
ing the central cornea. According to the patients, clinical symp-
toms first became apparent at 13 to 49 years of age (Table 1).
Decreased visual acuity was the common presenting complaint
(found in 85% of patients) followed by irritation and tearing
(45% of patients) and the presence of a white opacity (20% of
patients). Among patients who did not undergo penetrating
keratoplasty, the visual acuity ranged from counting fingers
to 20/30. Climatic droplet keratopathy (spheroidal degenera-
tion) was associated in 2 patients (5%), who not only had the
typical features of MCD, but also golden-colored spherical
deposits in the superficial cornea. None of the patients had
raised intraocular pressure or posterior segment abnormali-
ties. Out of 17 patients who underwent penetrating kerato-
plasty (PK), the grafts remained clear in all except 5 cases for
the period of follow up, which ranged from 0 to 14 years. The
grafts failed in five cases and in all of these instances the grafted
tissue became edematous, without clinical evidence of recur-
rent MCD. In 17 patients who had undergone keratoplasty (8
unilateral grafts, 9 bilateral grafts) diagnosis was confirmed
by histopathologic examination. Of the 36 patients studied,
14 were sporadic cases with no other affected relatives while
the rest had familial disease. Consanguinity was known to be
present in 20 out of 31 families.
PCR amplification and sequence analysis:  Genomic DNA
was extracted from 8-10 ml of blood samples obtained from
all the patients involved in the study and also from the normal
controls without any corneal diseases. The CHST6 gene is 16.9
kb in length and consists of 4 exons, of which only exon 4
contains the coding sequence of 1,189 bp. For amplification
of the CHST6 coding region, 3 primer pairs were used for 5'-
, middle, and 3'-segments as described by Akama et al. [18].
All PCR reactions were done (thermal cycler PTC 200 MJ
Research, Watertown, MA) using 75 ng genomic DNA in 25
µl reaction containing 1X PCR buffer (200 µM of dNTPs, 0.5
µM of each primer, 4% dimethyl sulfoxide [DMSO] and 1 U
Taq polymerase). PCR products were purified on Amicon col-
umns (Microcon PCR; Millipore, Bedford, MA) and directly
sequenced using fluorescent dideoxynucleotides (Big Dye
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TABLE 1. MUTATIONS OF THE CHST6 GENE AMONG PATIENTS WITH MACULAR CORNEAL DYSTROPHY
                                               Consequence   Restriction   Age (yrs)                    Corneal
Family     Mutation        Mutation type       in protein    site change   of onset    Consanguinity     graft
------   ------------   --------------------   -----------   -----------   ---------   -------------   ----------
   1     c.708-732del   Deletion (25 bp)       FS at R5        -              14             N         N
   2     c.744C>T       Nonsense               Q18X            Xmi1           26             N         Bilateral
   3     c.786-792del   Deletion (7 bp)        FS at P31       -              26             Y         N
   4     c.847G>A       Missense               G52D            Hinf1          13             Y         N
   5     c.847G>A       Missense               G52D            Hinf1          40             Y         Bilateral
   6     c.850C>T*      Missense               S53L            Eco241         23             Y         Unilateral
   7     c.850C>T*      Missense               S53L            Eco241         20             N         N
   8     c.872delC      Deletion (1 bp)        FS at F60       Mse1           15             Y         N
   9     c.890delC*     Deletion (1 bp)        FS at V66       -              43             N         N
  10     [c.985C>G,     Missense               S98W+F107S      -              14             N         Bilateral
         c.986C>G] +
         c.1012T>C
  11     c.1012T>C*     Missense               F107S           -              10             Y         Unilateral
  12     c.1012T>C*     Missense               F107S           -              15             Y         N
  13     c.1055C>G      Missense               F121L           BseN1          23             Y         N
  14     c.1061G>A      Nonsense               W123X           Cfr131         16             N         Bilateral
  15     c.1151C>A      Nonsense               C153X           -              34             N         Unilateral
  16     c.1279insACG   Insertion              R195-196ins     -              10             Y         Bilateral
  17     c.1296C>A      Missense               R202S           Hph1           21             Y         Bilateral
  18     c.1303C>A*     Missense               P204Q           Cfr421         49             Y         N
  19     c.1304-1306    Deletion + insertion   FS at P204      Cfr421         25             N         N
         del3insAT*
  20     [c.1321C>T +   Missense               S210F+D221E     -              29             Y         N
         c.1355C>G]
  21     c.1353G>T      Missense               D221Y           Nmuc1          19             Y         Bilateral
  22     c.1348insCTG   Insertion (in frame)   W219-220ins     -              17             N         Unilateral
  23     c.1348insCTG   Insertion (in frame)   W219-220ins     -              15             Y         Unilateral
  24     c.1348insCTG   Insertion (in frame)   W219-220ins     -              12             Y         N
  25     c.1348insCTG   Insertion (in frame)   W219-220ins     -              14             Y         N
  26     c.1355C>G      Missense               D221E           Nmuc1          13             Y         Unilateral
  27     c.1355C>G      Missense               D221E           Nmuc1       childhood         N         Bilateral
  28     c.1355C>G      Missense               D221E           Nmuc1          35             Y         Unilateral
  29     c.1617G>T      Nonsense               G309X           Tspr1          22             Y         N
  30     c.1731G>T      Nonsense               E347X           -              34             N         Unilateral
  31     c.1731G>T      Nonsense               E347X           -              15             Y         Bilateral
Shown are details of probands of the families studied and mutations identified. The asterisks (“*”) designate mutations reported previously. FS
indicates a frameshift. The last column indicates whether corneal grafts were performed and, if yes, whether they were bilateral or unilateral.
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Terminator Kit; Applied Biosystems Incorporated, Foster City,
CA) on an automated DNA sequencer (ABI Prism 377). The
sequences were compared with the published cDNA sequence
of CHST6 (AF219990) and mutations identified were excluded
from 75 control DNA samples using restriction enzymes where
appropriate. For mutations without changes in restriction en-
zyme sites, single strand conformation polymorphism (SSCP)
using fragments <300 bp in length amplified with overlap-
ping sets of primers or direct sequencing was performed.
RESULTS
 In the population analyzed, mutations in the coding region of
CHST6 were identified in all cases. We found 22 different
mutations and none of them were detected in a control popu-
lation of the same ethnic origin as determined by restriction
enzyme digests or SSCP analysis on at least 150 chromosomes,
suggesting that they are likely to be pathogenic mutations.
Out of the 22 identified mutations, there were 4 deletions,
2 insertions, 1 complex mutation consisting of deletion and
insertion, 5 nonsense and 10 missense mutations (Table 1). A
homozygous 25 bp deletion was identified (family 1), result-
ing in a frameshift at arginine-5, followed by 55 amino acids
of altered reading frame before a stop codon. A second ho-
mozygous deletion of 7 bp was found in family 3, producing a
frameshift at proline-31, with termination after 36 amino ac-
ids. In family 8, homozygous deletion of a single base C-872
was found, leading to a frameshift at phenylalanine-60, with
termination after eight amino acids. A heterozygous deletion
of C-890 predicting a frameshift at valine-66 and immediate
termination of protein at amino acid 70 was found in family 9.
In this family, the second mutation has not been identified
upon sequencing of the coding region. A complex homozy-
gous mutation, consisting of a deletion of GCG at nucleotide
1304 and an insertion of AT was seen in family 19, which
resulted in a frameshift at proline-204. A 174 amino acid
polypeptide of altered reading frame is predicted after the
frameshift.
Five nonsense mutations were found in 6 families, in-
volving the formation of stop codons at glutamine-18 (Q18X)
in family 2, tryptophan-123 (W123X) in family 14, cysteine-
153 (C153X) in family 15, glycine-309 (G309X) in family 29
and glutamic acid-347 (E347X) in families 30 and 31.
Two insertions resulting in an in-frame insertion of a single
amino acid were found. A recurrent homozygous insertion of
CTG at nucleotide 1348 in families 22-25 resulted in the in-
sertion of an extra amino acid tyrosine, after alanine-219.
Homozygous insertion of ACG in family 16 resulted in the
insertion of an arginine residue after leucine-195. Since there
is an “ACG” sequence from nucleotides 1277-1279 of the
CHST6 cDNA, the insertion of an ACG either at position 1276
or at 1279 would produce the same result. Hence the insertion
could have occurred at either of these positions with the re-
sulting amino acid sequence being identical in both cases.
Apart from these, we identified 10 missense mutations in
16 families (Table 1). Homozygous mutations identified were
glycine-52 to aspartic acid (G52D) in 2 families, serine-53 to
leucine (S53L) in 2 families, phenylalanine-107 to serine
(F107S) in 2 families, phenylalanine-121 to leucine (F121L)
in one family, arginine-202 to serine (R202S) in one family,
proline-204 to glutamine (P204Q) in one family, aspartic acid-
221 to glutamic acid (D221E) in 3 families, and aspartic acid-
221 to tyrosine (D221Y) in one family. Two novel compound
heterozygous missense mutations were identified in families
10 and 20. In family 10, changes of serine-98 to tryptophan
(S98W) and phenylalanine-107 to serine (F107S) were found
in two affected members of the family. In family 20, the
proband was a compound heterozygote for serine-210 to phe-
nylalanine (S210F) and aspartic acid-221 to glutamic acid
(D221E) missense mutations.
We failed to detect any apparent relationship between
CHST6 mutations and the clinical manifestations in the pa-
tients with MCD. Families with the same mutations had varia-
tions in the clinical features. For example, age of onset as well
as presence of deposits up to the corneoscleral limbus varied
among members of families 26-28 which had the D221E
change (Table 1). Truncating and non-truncating mutations
did not cause apparent differences in the age of onset of the
cases.
DISCUSSION
 Corneal N-acetyl glucosamine-6-O-sulfotransferase catalyzes
the transfer of a sulfate group to C6 of N-acetyl glucosamine
in keratan sulfate, a common component of corneal
proteoglycans. Structurally, this enzyme shares conserved se-
quences with many sulfotransferases (NCBI Conserved Do-
main Database), consisting of a single α/β domain [23]. It is
presumed to play a key role in the production of corneal keratan
sulfate [24,25].
We studied a cohort of 36 patients (31 unrelated) with
MCD, which is a common corneal dystrophy in India. Twenty-
two mutations including 17 novel mutations were identified.
A notable feature of the mutations in this series is that 10 are
predicted to result in a premature termination of the encoded
protein and would be expected to produce functionally null
alleles. As shown in Table 1 the majority of the unrelated pa-
tients (28) had homozygous pathogenic mutations within the
coding region of CHST6. Two patients (from families 10 and
20), were compound heterozygotes for two missense muta-
tions. However, in 1 family (family 9), only a single heterozy-
gous change was detected within the coding region of CHST6.
Because the second mutation was not identified in the coding
region, it is possible that it is located in the promoter or in a
non-coding region of the gene.
Overall, the data indicate a high degree of heterogeneity
among the patients studied. Similar heterogeneity has been a
feature in other studies carried out on individuals with MCD
in other populations including those from Britain [22], France
[26], Iceland [21], India [27], Japan [28], Saudi Arabia [29],
United States of America [30], and Vietnam [31]. Warren et
al. [27] in their study on MCD in a Southern Indian popula-
tion also noted a high degree of mutational heterogeneity. We
found only three of the mutations that were reported by them
in our patient population (see below). The spectrum of muta-
tions described in their study comprised missense, deletions,
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and complex mutations. In contrast to our study they did not
observe any nonsense mutations [27]. Since our patients rep-
resent diverse regions, our data do not permit conclusions as
to whether any of the mutations are specific to an ethnic sub-
group. An analysis of a larger cohort of patients would be re-
quired to determine if nonsense mutations are a significant
type of mutation in MCD patients.
To assess the significance of the identified missense mu-
tations, an alignment of protein sequences of the conserved
domains from several sulfotransferases of human and mouse
origin was examined. As can be seen from Table 2, all resi-
dues mutated are highly conserved, suggesting that these amino
acids are essential for the structure and function of the pro-
tein. Five mutations involve the conserved domains required
for interacting with the sulfate donor 3'-phospho adenosine
5'-phosphosulfate (PAPS) [32]. Mutations G52D and S53L are
located within the 5'-PSB (5'-phosphosulfate-binding) domain
which interacts with the 5'-phosphate group of PAPS and is
highly conserved among all sulfotransferases known to date
[23]. The R202S, P204Q, and S210F involve the 3'-PB (3'-
phosphate-binding) domain, the highly conserved domain in-
teracting with the 3'-phosphate of PAPS. Five of the muta-
tions identified in the present study were previously reported;
c.850C>T (S53L), c.890delC, and del1304-1306insAT were
reported in Indian patients [27], the F107S mutation has been
reported previously in a British family [22] and the P204Q
mutation has been recently reported in Japanese patients [28].
The only substitution that involved replacement with a
chemically similar amino acid is D221E (Table 1). The occur-
rence of this change in probands from 3 families (Table 1,
families 26-28) as a homozygous change and in one family
(family 20) as a heterozygous change, together with its ab-
sence in 75 unrelated control individuals supports the conclu-
sion that it is pathogenic. Structural modeling of normal and
mutant proteins as well as in vitro studies on the properties of
the wild type and mutant proteins may be required to deter-
mine the exact consequences of this change. It is possible that
a mutation of aspartic acid-221 causes changes in local struc-
ture or alters protein stability or processing, thus leading to
deficient enzyme activity.
Analysis of clinical parameters indicated that most pa-
tients in our study had similar features. There were no consis-
tent differences in phenotype between patients with the vari-
ous amino acid substitutions and truncating mutations. Bio-
chemical studies on the enzymatic activity of the mutant pro-
teins identified in our study may help elucidate the role of
specific residues on the function of the CHST6 gene product.
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TABLE 2. SEQUENCE ALIGNMENT OF SULFOTRANSFERASES SHOWING CONSERVATION OF AMINO ACIDS MUTATED IN MCD PATIENTS
                                G52D,                                  R202S,
                                S53L      S98W      F107S     F121L     P204Q    D221E/Y    S210F
----------------------------   -------   -------   -------   -------   -------   -------   -------
Human corneal                  S G S S   R S V F   D V F D   L F Q W   V R D P   A R D N   L R S R
GlcNAc 6-O-sulfotransferase
(AF219990)
Human intestinal GlcNAc        S G S S   R S I F   D V F D   F F N W   V R D P   A R D N   L R S R
6-O-sulfotransferase
(AF246718)
N-acetylglucosamine-           S G S S   R A V F   S V F D   L F Q W   V R D P   M I D S   F R S R
6-O-sulfotransferase (human)
(AF131235)
Human chondroitin              T G S S   R S L F   S V L R   L F R W   F R D P   L R E S   H N S R
6-sulfotransferase-2
(AB037187)
Mouse L-selectin ligand        S G S S   R S V F   S V F D   L F Q W   V R D P   V V D S   F R S R
sulfotransferase
(AF131235)
N-acetylglucosamine-           S G S S   R S V F   D V F D   L F Q W   V R D P   A R D N   L R S R
6-O-sulfotransferase (Mouse)
(AF176841)
Mouse chondroitin              T G S S   K Q L L   Y V L E   L F R R   V R D P   Y E N W   L A S R
6-sulfotransferase
(AB008937)
The protein sequences of the sulfotransferases shown were aligned using the software Omiga version 2.0 (Oxford Molecular Ltd., Cambridge,
England). Residues mutated along with flanking amino acids are shown in this table. Mutations are indicated at the top of each column.
GenBank accession numbers of the sequences are given in parentheses.
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